Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Second quarter in brief
- In April, the US Food and Drug Administration (FDA) granted Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma
- The primary clinical endpoint from the Phase III trial of laquinimod in RRMS (CONCERTO study) was not met. The secondary endpoints (brain atrophy, relapse rate and MRI-data) were achieved and in line with previous studies
- Out-licensing activities are continuing for tasquinimod, paquinimod and SILC
Events after the end of the period
- Helén Tuvesson succeeds Tomas Leanderson as President & CEO of the company July 1, 2017
- In July, a patent application for the use of ANYARA in combination with PD-1 inhibitors for the treatment of cancer was published on WIPO's (World Intellectual Property Organization) website www.wipo.int
Financial summary
| SEK M | April-June | Jan.-June | Full-year | |||||
| 2017 | 2016 | 2017 | 2016 | 2016 | ||||
| Net sales | 5.1 | 3.9 | 9.8 | 7.9 | 19.0 | |||
| Operating loss | -23.1 | -14.5 | -37.7 | -30.6 | -55.1 | |||
| Loss for the period | -24.4 | -15.5 | -40.2 | -32.3 | -59.6 | |||
| Loss per share, before and after dilution (SEK) | -0.25 | -0.17 | -0.42 | -0.36 | -0.65 | |||
| Cash and cash equivalents (at the end of the period) | 47.7 | 57.4 | 77.7 | |||||
For further information, please contact:
| Helén Tuvesson, President & CEO Tel: +46 (0)46-19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: 046 (0)46-19 20 00 |
The report is also available at www.activebiotech.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/0c8b53eb-d197-4c8b-bd63-aa1de2d640d2
